Document Detail


Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers.
MedLine Citation:
PMID:  23276940     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Receptor tyrosine kinases (RTK) are key targets for novel cancer therapeutics since they activate multiple oncogenic signalling pathways. Also, they are inherently 'druggable' due to their small ATP-dependent kinase domains (inhibitable by small molecules) and cell surface location which renders them accessible to monoclonal antibody-based therapies. The epidermal growth factor receptor (EGFR) is overexpressed in the majority of SCCHN cases and this review focuses primarily on the progress made in targeting the EGFR for the therapy of SCCHN by both small molecules and antibody-based therapies. We then discuss the overlapping and distinct molecular markers of response, innate or acquired resistance to each modality, and how these may be overcome. We also consider other RTKs overexpressed in this disease that may impact on responses and/or provide additional targets for combination therapy.
Authors:
Carol Box; Miriam Zimmermann; Suzanne Eccles
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  18     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-06-12     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  520-42     Citation Subset:  IM    
Affiliation:
Tumour Biology and Metastasis Team, CR-UK Cancer Therapeutics Unit, McElwain Laboratories, The Institute of Cancer Research, Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use*
Carcinoma, Squamous Cell / drug therapy*
Drug Resistance, Neoplasm
HSP90 Heat-Shock Proteins / antagonists & inhibitors
Head and Neck Neoplasms / drug therapy*
Humans
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins c-met / antagonists & inhibitors
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
Receptor, Epidermal Growth Factor / antagonists & inhibitors*
Receptor, IGF Type 1 / antagonists & inhibitors
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
Tumor Markers, Biological
Grant Support
ID/Acronym/Agency:
C309/A8274//Cancer Research UK
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; 0/HSP90 Heat-Shock Proteins; 0/Protein Kinase Inhibitors; 0/Tumor Markers, Biological; 0/panitumumab; EC 2.7.10.1/Proto-Oncogene Proteins c-met; EC 2.7.10.1/Receptor Protein-Tyrosine Kinases; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptor, IGF Type 1; EC 2.7.10.1/Receptors, Vascular Endothelial Growth Factor; PQX0D8J21J/cetuximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  TGM2 and implications for human disease: role of alternative splicing.
Next Document:  Ovarian cancer as a genetic disease.